Prevalence of COVID-19-associated pneumonia signs on chest computed tomography in cancer patients: the ARILUS study
Open Access
- 31 July 2025
- journal article
- Published by Sechenov University in Sechenov Medical Journal
- Vol. 16 (2) , 4-17
Abstract
Aim. To study the prevalence of pneumonia features associated with 2019 coronavirus disease (COVID-19) in cancer patients based on chest computed tomography (CT) data using an artificial intelligence (AI) algorithm.Materials and methods. A cross-sectional study was conducted as part of the ARILUS project. Using multitarget AI, CT images of 1148 patients examined at the Arkhangelsk Clinical Oncology Dispensary from 01.04.2020 to 31.12.2021 were analyzed. Patients were divided into groups: without signs of pneumonia (n = 592, 51.6%) and with signs of pneumonia (n = 556, 48.4%). In 95.3% of patients with pneumonia, the lesion volume was less than 25% (CT-1). Using multivariate Poisson regression, adjusted prevalence ratios (aPR) with 95% confidence intervals (CI) were calculated.Results. For demographic characteristics such as gender, age, place of residence, no relationship with the presence of signs of COVID-19 pneumonia was established. Topography of neoplasm is associated with the presence of signs of COVID-19 pneumonia (reference group – cancers of the female genital organs): lung cancer – aPR 1.87; 95% CI: 1.40–2.49; head and neck cancers – aPR 1.85; 95% CI: 1.32–2.58; upper gastrointestinal tract – aPR 1.51; 95% CI: 1.12–2.04; breast cancer – aPR: 1.38; 95% CI: 1.00–1.90; p < 0.01. The presence of pulmonary emphysema is associated with signs of COVID-19 pneumonia: aPR 1.25; 95% CI: 1.09–1.45, p = 0.002. With an increase in the Agatston score (AS) reflecting coronary artery calcification (reference group absence of calcification), the association with the presence of signs of COVID-19 pneumonia increased – for AS 1–99: aPR 1.24; 95% CI: 1.05–1.47; AS 100– 299: aPR 1.58; 95% CI: 1.33–1.87; AS 300 and above: aPR 1.61; 95% CI: 1.36–1.90; p < 0.001 for a linear trend.Conclusion. Factors associated with the detection of COVID-19 pneumonia among cancer patients include the localization of neoplasms in the lungs, head and neck organs, upper gastrointestinal tract, breast, and as well as the presence of signs of emphysema and coronary calcification according to CT dataKeywords
This publication has 26 references indexed in Scilit:
- Risks of major arterial and venous thrombotic diseases after hospitalisation for influenza, pneumonia, and COVID-19: A population-wide cohort in 2.6 million people in WalesThrombosis Research, 2024
- Clinical data and quantitative CT parameters combined with machine learning to predict short-term prognosis of severe COVID-19 in the elderlyHeliyon, 2024
- Cannabis, Tobacco Use, and COVID-19 OutcomesJAMA Network Open, 2024
- The impact of smoking on COVID-19-related mortality: a Brazilian national cohort studyAddictive Behaviors, 2024
- Impact of the COVID-19 pandemic on breast cancer patient pathways and outcomes in the United Kingdom and the Republic of Ireland – a scoping reviewBritish Journal of Cancer, 2024
- Fewer cancer diagnoses during the COVID-19 epidemic in the NetherlandsThe Lancet Oncology, 2020
- Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, ChinaThe Journal of Infectious Diseases, 2020
- Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, ChinaScience China Life Sciences, 2020
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countriesThe Lancet, 2018
- Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)The Lancet, 2015